Azer-cel is an off the shelf CD19 CAR-T. OnCARlytics marks the solid tumour cancer with a CD19 target. Might be a big market for Azer-cel as well with the possible combination therapy with OnCARlytics.
I don’t think the team at Imugene thought…we don’t have enough to do, let’s go and get a new drug to play with…there has to be short term value in DLBCL and long term value in OnCARlytics to this Azer-cel play.
I believe the team at Imugene know how to combine drugs for the best effect. I haven’t come across anywhere that Precision BioSciences combined Azer-cel and IL-2, that appears to be an Imugene initiative.
I am positive that this will all piece together nicely as it progresses and value will return.
IMU Price at posting:
1.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)